AMGN News 122.26 07/25/2014 04:32:21 Amgen Inc (AMGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen Inc (AMGN) 122.26 $AMGN

Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
PR Newswire - Fri Jul 25, 1:30AM CDT
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

Final Glance: Biotechnology companies
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

FDA reviewing what could be first biosimilar drug
AP - Thu Jul 24, 4:33PM CDT
WASHINGTON, D.C. (AP) — The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug.

Amgen Announces Webcast of 2014 Second Quarter Financial Results
PR Newswire - Thu Jul 24, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

Surveyed U.S. and EU5 Dermatologists Indicate that Short-Term and Long-Term Effects on Psoriatic Plaque Clearance are Two Attributes that Most Strongly Influence Prescribing Decisions in Moderate to Severe Psoriasis
PR Newswire - Thu Jul 24, 1:00PM CDT
Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis. Emerging therapies that offer improved effect in these attributes over current therapies would be well received and poised for strong uptake. Based on thought leaders' opinions and clinical trial data, emerging therapies, especially IL-17 inhibitors (Novartis's secukinumab, Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab, Eli Lilly's ixekizumab) have potential, owing to their improved efficacy relative to current therapies in improving psoriatic plaques. However, based on currently available data and physicians' opinions, emerging therapies lack the efficacy, safety and tolerability, and/or delivery features that would allow them to offer better overall clinical profiles than that of Janssen's Stelara.

Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.

Midday Glance: Biotechnology companies
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

Early Glance: Biotechnology companies
AP - Thu Jul 24, 10:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies

The Zacks Analyst Blog Highlights: AbbVie, Shire, Amgen, InterMune and Biogen
PR Newswire - Thu Jul 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), Amgen (Nasdaq:AMGN-Free Report), InterMune (Nasdaq:ITMN-Free Report) and Biogen (Nasdaq:BIIB-Free Report).

Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.

Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25

Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.75% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Amgen Rises 1.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 4:05PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $119.35 to a high of $121.27. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $119.34 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why Investors Continue to Flee Aegerion Stock
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Although it's easy to generate huge commercial expectations for rare disease drugs (especially with orphan drug pricing in the United States), many companies report very underwhelming sales figures once the drug is brought to market. Even for drugs...

Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Tue Jul 22, 2:20AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.

Astellas Up on Pipeline Update, Oncology in Focus (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:07PM CDT
Astellas Pharma, Inc. (ALPMY) provided a comprehensive overview of its initiatives towards innovation, research and development and its corporate strategy.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 89

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 24

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 183

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 155

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 106

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 52

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Welcomes New Leaders to Enhance Transactions Team

Updated Category News Views 162

FTI Consulting Expands Expertise in Transactions Practice FTI Consulting, Inc. has recently announced the addition of two seasoned M&A professionals to its Transactions practice within the Corporate Finance & Restructuring segment. This strategic move aims to enhance their offerings and support clients in managing complex transactions. Introduction of M&A Experts The...

Continue Reading
BetaNXT Recognized as Leader in Wealth Management Innovation

Updated Category News Views 309

BetaNXT Earns Recognition as a Trendsetter in Wealth Management BetaNXT has captured attention in the financial technology landscape, particularly with its groundbreaking DataXChange platform. This innovative solution is designed to enhance modernization and innovation in wealth management, fostering business growth through a connected data ecosystem. Finalist in...

Continue Reading
OysterLink Sees Record Interest in Hospitality Job Searches

Updated Category News Views 124

Surging Demand for Restaurant and Hospitality Positions New analysis indicates that interest in restaurant and hospitality jobs has surged, reaching the highest level seen in five years. This summer's data from OysterLink's platform, combined with nationwide Google Trends, showcases a remarkable uptick in searches and applications, highlighting a strong rebound in the...

Continue Reading
Innovative Lithium Battery Solutions Enhanced by ITU and Huawei

Updated Category News Views 315

Joint Innovations in Lithium Battery Technology At the prestigious Global Digital Power Summit, a collaboration between the International Telecommunication Union (ITU) and Huawei brought significant attention to lithium battery applications for telecom sites. With industry leaders and experts congregating, the dialogue centered around technological advancements aimed at...

Continue Reading
Licel vTEE Continues to Lead in EMVCo TEE Success

Updated Category News Views 130

Licel vTEE Achieves EMVCo Approval Again The groundbreaking virtual trusted execution environment, Licel vTEE, stands out as the only SBMP TEE to receive evaluation and approval from EMVCo. This marks another milestone in the continued recognition of Licel's innovative technology. Unprecedented Recognition for Android Platform Licel's vTEE has received re-evaluation and...

Continue Reading